+$75.2M
Net Activity
Institutions Holding
137
Popularity Rank
#3770
Avg Weight
0.02%
Total Value
$451.2M
137 institutions currently hold ABCL, with 73 net buyers and 62 net sellers this quarter.
Institutional Moves (Q1 2026)
Neutral
Based on recent trading activity
Net Selling Institutions
62
Net Buying Institutions
73
Top 5 by Value
+$299.3M
Total Buy Value
$126.3M
Total Sell Value
73
Net Buyers
62
Net Sellers
No Form 144 planned sale filings in the last 90 days
No Schedule 13D/13G filings for this ticker
1
Filings (14d)
AbCellera Biologics appointed Dr. Lynn Seely as a new Class III director on June 30, 2026. Her term runs through the 2029 annual shareholder meeting. She meets Nasdaq's independence standards and will follow the standard non-employee director compensation plan. She currently has no board committee assignments and no material ties to the company.
View Full Filing (SEC EDGAR)The most-added stocks by 13F institutions this quarter
Institutions Holding
6,150
Total reported value
$2.1T
3245 13F institutions increased their position this quarter
Institutions Holding
5,957
Total reported value
$1.5T
3028 13F institutions increased their position this quarter
Institutions Holding
5,764
Total reported value
$3.0T
2743 13F institutions increased their position this quarter